Selenium, a supplement taken daily by millions in hopes of protection against cancer and a host of other diseases, has proven to be of no benefit in reducing a patient's risk of developing lung cancer - either a recurrence or second primary malignancy, according to results of an international Phase III clinical trial.Still think they have any idea what an effective supplement is?
Results from the decade-long study, initiated by the Eastern Cooperative Oncology Group, were presented at the American Society of Clinical Oncology 2010 Annual Meeting by Daniel D. Karp, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center.
Thursday, June 24, 2010
No Benefit In Prevention Of Lung Cancer In Clinical Trial Of Selenium
Oops.
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment